Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCT NASDAQ:BLUE OTCMKTS:CSLLY NYSE:NVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$17.32-4.0%$15.38$8.04▼$25.88$489.87M2.39516,680 shs644,225 shsBLUEbluebird bio$4.97$4.78$3.20▼$25.10$48.67M0.27452,966 shsN/ACSLLYCSL$68.420.0%$79.16$65.13▼$101.73$66.27B0.78156,347 shs241,904 shsNVSNovartis$124.12-2.8%$121.72$96.06▼$130.46$269.76B0.63997,220 shs1.86 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics-3.99%-2.97%-9.84%+39.90%-17.45%BLUEbluebird bio0.00%0.00%0.00%0.00%-57.29%CSLLYCSL-0.01%+0.10%-23.01%-11.76%-32.16%NVSNovartis-2.74%-4.35%+2.35%+4.00%+7.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$17.32-4.0%$15.38$8.04▼$25.88$489.87M2.39516,680 shs644,225 shsBLUEbluebird bio$4.97$4.78$3.20▼$25.10$48.67M0.27452,966 shsN/ACSLLYCSL$68.420.0%$79.16$65.13▼$101.73$66.27B0.78156,347 shs241,904 shsNVSNovartis$124.12-2.8%$121.72$96.06▼$130.46$269.76B0.63997,220 shs1.86 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics-3.99%-2.97%-9.84%+39.90%-17.45%BLUEbluebird bio0.00%0.00%0.00%0.00%-57.29%CSLLYCSL-0.01%+0.10%-23.01%-11.76%-32.16%NVSNovartis-2.74%-4.35%+2.35%+4.00%+7.66%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 3.00Buy$50.57191.98% UpsideBLUEbluebird bio 2.14Hold$25.75418.11% UpsideCSLLYCSL 4.00Strong BuyN/AN/ANVSNovartis 2.00Hold$120.33-3.05% DownsideCurrent Analyst Ratings BreakdownLatest CSLLY, NVS, BLUE, and ARCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025NVSNovartisThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Sell$119.00 ➝ $118.009/4/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.008/22/2025ARCTArcturus TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$63.00 ➝ $54.008/21/2025NVSNovartisDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/12/2025ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.00 ➝ $49.008/12/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$45.00 ➝ $42.008/8/2025NVSNovartisMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$123.007/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform7/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Outperform$32.00 ➝ $35.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$152.31M3.09N/AN/A$8.90 per share1.95BLUEbluebird bio$103.95M0.47N/AN/A$35.59 per share0.14CSLLYCSL$15.56B4.26$3.98 per share17.20$20.07 per share3.41NVSNovartis$50.32B5.21$10.40 per share11.93$21.59 per share5.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$80.94M-$2.23N/AN/AN/A-49.26%-24.87%-17.75%11/6/2025 (Estimated)BLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%N/ACSLLYCSL$3.00BN/A0.0016.731.58N/AN/AN/A10/30/2025 (Estimated)NVSNovartis$11.94B$6.8718.0714.091.7925.64%41.08%16.83%11/4/2025 (Estimated)Latest CSLLY, NVS, BLUE, and ARCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025ARCTArcturus Therapeutics-$1.11-$0.34+$0.77-$0.34$17.64 million$28.30 million7/17/2025Q2 2025NVSNovartis$2.38$2.42+$0.04$2.06$13.94 billion$14.05 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus TherapeuticsN/AN/AN/AN/AN/ABLUEbluebird bioN/AN/AN/AN/AN/ACSLLYCSL$1.522.22%N/AN/AN/ANVSNovartis$2.602.09%N/A37.85%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A5.905.90BLUEbluebird bio0.370.510.33CSLLYCSL0.451.860.85NVSNovartis0.530.820.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%BLUEbluebird bio87.43%CSLLYCSL0.03%NVSNovartis13.12%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics16.60%BLUEbluebird bio1.40%CSLLYCSLN/ANVSNovartis0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18027.16 million22.65 millionOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableCSLLYCSL32,698968.42 millionN/ANot OptionableNVSNovartis75,8832.11 billion2.11 billionOptionableCSLLY, NVS, BLUE, and ARCT HeadlinesRecent News About These CompaniesGeneos Wealth Management Inc. Acquires 3,126 Shares of Novartis AG $NVSSeptember 13 at 5:35 AM | marketbeat.comSCS Capital Management LLC Invests $586,000 in Novartis AG $NVSSeptember 13 at 4:45 AM | marketbeat.comNovartis AG $NVS Shares Purchased by Great Lakes Advisors LLCSeptember 13 at 4:19 AM | marketbeat.comNovartis AG $NVS Shares Sold by Jones Financial Companies LllpSeptember 13 at 3:59 AM | marketbeat.comGoldman Sachs Downgrades Novartis AG - Depositary Receipt () (NVS)September 12 at 2:48 PM | msn.comNovartis Catches a ‘Sell.' Goldman Sachs Says the Stock Is Overvalued.September 12 at 12:11 PM | barrons.comNovartis downgraded to Sell from Neutral at Goldman SachsSeptember 12 at 9:47 AM | msn.comAscent Group LLC Grows Position in Novartis AG $NVSSeptember 12 at 6:10 AM | marketbeat.comNovartis AG Faces Sell Rating Amid Overvaluation and Looming Generic CompetitionSeptember 12 at 2:51 AM | tipranks.comGoldman Sachs Group Inc. Has $408.07 Million Stock Position in Novartis AG $NVSSeptember 11 at 4:43 AM | marketbeat.comIntegrated Wealth Concepts LLC Sells 2,940 Shares of Novartis AG $NVSSeptember 11 at 4:08 AM | marketbeat.comNVS to Acquire TRML, Add Phase III Cardiovascular Drug to PipelineSeptember 10 at 12:11 PM | zacks.com5 Large Drug Stocks to Watch Despite Industry & Macro HeadwindsSeptember 10 at 12:11 PM | zacks.comNewEdge Advisors LLC Has $8.59 Million Position in Novartis AG $NVSSeptember 10 at 5:17 AM | marketbeat.comBuyout Of Tourmaline By Novartis Primarily On Pacibekitug IL-6 Novel Mode Of ActionSeptember 9, 2025 | seekingalpha.comWhy Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense'September 9, 2025 | msn.comNovartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 BillionSeptember 9, 2025 | investors.comNovartis' Moonshot Cancer Therapy Could Be Future Growth Driver...September 9, 2025 | marketbeat.comNovartis to acquire Tourmaline Bio in $1.4B all-cash dealSeptember 9, 2025 | msn.comThis Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It.September 9, 2025 | barrons.comTourmaline Bio Merges with Novartis for $1.4 BillionSeptember 9, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025Eyes on the Sky: AST SpaceMobile Prepares for Commercial LaunchBy Jordan Chussler | September 8, 2025Novartis' Moonshot Cancer Therapy Could Be Future Growth DriverBy Chris Markoch | September 9, 2025CSLLY, NVS, BLUE, and ARCT Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$17.32 -0.72 (-3.99%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$17.14 -0.18 (-1.01%) As of 09/12/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.bluebird bio NASDAQ:BLUEbluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.CSL OTCMKTS:CSLLY$68.42 -0.01 (-0.01%) As of 09/12/2025 03:59 PM EasternCSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.Novartis NYSE:NVS$124.12 -3.58 (-2.80%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$123.70 -0.42 (-0.34%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
